Kazia Reports Positive Final Data From P-II Study of Paxalisib to Treat Patients with Glioblastoma
Shots:
- The P-II study evaluated the safety and tolerability of paxalisib (60 mg QD) vs temozolomide at US (6 sites) in 30 patients with unmethylated MGMT newly diagnosed glioblastoma
- Result: 60mg QD MTD dose defined; mOS (n=30): 15.7 mos. vs 12.7mos. mPFS (n=30): 8.4mos. vs. 5.3mos. In mITT (n=27) OS: 15.9mos.
- Kazia plans to report the final result in Q1’22. In 2022 investigators are also planning to submit and publish a manuscript to a peer-reviewed academic journal
Ref: PR Newswire | Image: Kazia
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com